Metastatic-Breast-Cancer

Conference Coverage

Real-World Incidence of Thromboembolic Events in Patients With Metastatic Breast Cancer Treated With Ribociclib

12/07/2021

Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.

Study findings show patients...

12/07/2021

Journal of Clinical Pathways

.st0 {fill: #000;}

Conference Coverage

Budget Impact of Blood-Based Biomarker Assay in Patients With Metastatic Breast Cancer

12/07/2021

Janelle Bradley ;

Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the...

Use of a blood-based biomarker...

12/07/2021

Journal of Clinical Pathways

.st0 {fill: #000;}

Conference Coverage

Biomarker Testing and Alpelisib Treatment Patterns for Metastatic Breast Cancer in the Community Oncology Setting

12/07/2021

Janelle Bradley ;

A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.

A study presented at the 2021...

12/07/2021

Journal of Clinical Pathways

.st0 {fill: #000;}

Conference Coverage

Oncologists’ Perspectives on Patient-centered Dosing for Metastatic Breast Cancer

12/06/2021

Janelle Bradley ;

Medical oncologists reported that a high percentage of patients experience distressing toxicity, a need for acute care, and dose interruptions with standard delivery of therapy for metastatic breast cancer.

Medical oncologists reported...

12/06/2021

Journal of Clinical Pathways

.st0 {fill: #000;}

Conference Coverage

Third-Line Chemotherapy With or Without Trastuzumab-Based Therapy for Metastatic Breast Cancer

12/06/2021

Janelle Bradley ;

The inclusion of trastuzumab-based therapy with chemotherapy was associated with improved survival outcomes compared with chemotherapy alone for the third-line treatment of metastatic breast cancer.

The inclusion of...

12/06/2021

Journal of Clinical Pathways

.st0 {fill: #000;}

Conference Coverage

Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases

12/06/2021

Janelle Bradley ;

Palbociclib plus letrozole is associated with improved outcomes compared to letrozole alone for the first-line treatment of patients with HR-positive, HER2-negative metastatic breast cancer with lung or liver metastases.

Palbociclib plus letrozole is...

12/06/2021

Journal of Clinical Pathways

Metastatic Breast Cancer

Tracks

Specialties

Events

Year Round Education

HMP Global Products